-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
THE POWER & SPEED OF
NANOPARTICLE TECHNOLOGY
NANOPARTICLE TECHNOLOGY
Novavax creates transformational vaccines that address some of the world’s most pressing infectious diseases
Our approach to science
We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.
From respiratory diseases and beyond, our vaccine and adjuvant technology can be applied to address current and emerging global health threats.

SCIENCE & TECHNOLOGY
Matrix-M™ adjuvant technology
Our saponin-based Matrix-M™ adjuvant enhances the immune response and has a dose-sparing effect, both of which are critical to successful vaccine development.

SCIENCE & TECHNOLOGY
Recombinant nanoparticle vaccine technology
We are committed to delivering novel products that leverage our innovative proprietary recombinant protein-based nanoparticle technology to prevent a broad range of infectious diseases.

